Bristol Myers Squibb Total Assets 2010-2022 | BMY
Bristol Myers Squibb total assets from 2010 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Bristol Myers Squibb total assets for the quarter ending December 31, 2022 were $96.820B, a 11.43% decline year-over-year.
- Bristol Myers Squibb total assets for 2022 were $96.82B, a 11.43% decline from 2021.
- Bristol Myers Squibb total assets for 2021 were $109.314B, a 7.74% decline from 2020.
- Bristol Myers Squibb total assets for 2020 were $118.481B, a 8.82% decline from 2019.
Bristol Myers Squibb Annual Total Assets
(Millions of US $) |
| 2022 |
$96,820 |
| 2021 |
$109,314 |
| 2020 |
$118,481 |
| 2019 |
$129,944 |
| 2018 |
$34,986 |
| 2017 |
$33,551 |
| 2016 |
$33,707 |
| 2015 |
$31,748 |
| 2014 |
$33,749 |
| 2013 |
$38,592 |
| 2012 |
$35,897 |
| 2011 |
$32,970 |
| 2010 |
$31,076 |
| 2009 |
$31,008 |
Bristol Myers Squibb Quarterly Total Assets
(Millions of US $) |
| 2022-12-31 |
$96,820 |
| 2022-09-30 |
$98,196 |
| 2022-06-30 |
$100,357 |
| 2022-03-31 |
$103,034 |
| 2021-12-31 |
$109,314 |
| 2021-09-30 |
$110,893 |
| 2021-06-30 |
$110,797 |
| 2021-03-31 |
$112,435 |
| 2020-12-31 |
$118,481 |
| 2020-09-30 |
$125,536 |
| 2020-06-30 |
$128,076 |
| 2020-03-31 |
$129,285 |
| 2019-12-31 |
$129,944 |
| 2019-09-30 |
$57,433 |
| 2019-06-30 |
$55,163 |
| 2019-03-31 |
$34,834 |
| 2018-12-31 |
$34,986 |
| 2018-09-30 |
$33,734 |
| 2018-06-30 |
$32,641 |
| 2018-03-31 |
$33,083 |
| 2017-12-31 |
$33,551 |
| 2017-09-30 |
$33,977 |
| 2017-06-30 |
$33,409 |
| 2017-03-31 |
$32,937 |
| 2016-12-31 |
$33,707 |
| 2016-09-30 |
$33,727 |
| 2016-06-30 |
$32,831 |
| 2016-03-31 |
$31,892 |
| 2015-12-31 |
$31,748 |
| 2015-09-30 |
$31,779 |
| 2015-06-30 |
$31,954 |
| 2015-03-31 |
$33,579 |
| 2014-12-31 |
$33,749 |
| 2014-09-30 |
$33,450 |
| 2014-06-30 |
$33,503 |
| 2014-03-31 |
$33,424 |
| 2013-12-31 |
$38,592 |
| 2013-09-30 |
$36,804 |
| 2013-06-30 |
$36,252 |
| 2013-03-31 |
$35,958 |
| 2012-12-31 |
$35,897 |
| 2012-09-30 |
$36,044 |
| 2012-06-30 |
$31,667 |
| 2012-03-31 |
$32,408 |
| 2011-12-31 |
$32,970 |
| 2011-09-30 |
$32,014 |
| 2011-06-30 |
$31,833 |
| 2011-03-31 |
$30,851 |
| 2010-12-31 |
$31,076 |
| 2010-09-30 |
$31,885 |
| 2010-06-30 |
$31,051 |
| 2010-03-31 |
$30,753 |
| 2009-12-31 |
$31,008 |
| 2009-09-30 |
$30,951 |
| 2009-06-30 |
$29,809 |
| 2009-03-31 |
$29,693 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$140.576B |
$46.159B |
|
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
|
